Sunitinib promotes MYCN protein degradation and inhibit VEGF secretion in neuroblastoma.

<p>(<b>A</b>) Effect of sunitinib on GSK3β phosphorylation and on MYCN total protein in MYCN amplified NB cell lines. (*p≤0.05; ** p≤0.01). (<b>B</b>) Effect of sunitinib on MYCN mRNA evaluated by real time PCR after 72 h of treatment with the drug and represented as relative mRNA level ± SEM (n≥3). (<b>C</b>) ELISA analysis of VEGF secreted to cell culture medium by SK-N-BE(2) cell line after 72 hours of treatment with sunitinib (5 µM), rapamycin (20 nM) or combinations of sunitinib (5 µM) with rapamycin (20 nM) or PD98059 (20 µM). Bars are means ± SEM of three experiments (*p≤0.05 vs. untreated control; †p≤0.05 vs. rapamycin single treatment).